Axsome Therapeutics (AXSM) Price & Analysis

Compare

2,262 Followers

AXSM Stock Chart & Stats

$127.06

-$0.23(-0.27%)

At close: Jan 08 4:00 PM EST

$127.06

-$0.23(-0.27%)

Day’s Range― - ―

52-Week Range$75.56 - $139.13

Previous CloseN/A

Volume140.83K

Average Volume (3M)502.19K

Market Cap

$6.47B

Enterprise Value$5.08B

Total Cash (Recent Filing)$303.02M

Total Debt (Recent Filing)$215.29M

Price to Earnings (P/E)―

Beta0.91

Next Earnings

Nov 03, 2025

EPS Estimate

-0.87

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.97

Shares Outstanding49,901,485

10 Day Avg. Volume493,808

30 Day Avg. Volume502,194

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.79

Enterprise Value/Revenue10.27

Enterprise Value/Gross Profit11.22

Enterprise Value/Ebitda-22.60

Forecast

1Y Price Target

$173.25

Price Target Upside36.35% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering16

Bulls Say, Bears Say

Bulls Say

Pipeline DevelopmentAxsome's pipeline has several assets in late-stage development or approaching regulatory submission, increasing investor interest.

Product Launch PerformanceThe early launch of Symbravo for treating acute migraine is performing ahead of sales expectations, indicating strong market reception.

Sales GrowthAxsome completed a sales force expansion for Auvelity, adding 40 reps to the sales force, which is expected to drive TRx growth.

Bears Say

Product Coverage LimitationsPayer coverage for SYMBRAVO is currently at approximately 38% of all lives covered, indicating room for improvement.

Product Sales DecreaseSymbravo experienced a week-over-week decrease in both TRx and NRx figures after previously high growth.

Axsome Therapeutics News

Axsome Therapeutics price target raised to $194 from $191 at Morgan Stanley

Morgan Stanley analyst Sean Laaman raised the firm’s price target on Axsome Therapeutics (AXSM) to $194 from $191...

4d ago

AXSM

Axsome Therapeutics recognizes Mental Illness Awareness Week

Axsome Therapeutics (AXSM) announced it is recognizing Mental Illness Awareness Week, MIAW, alongside the national mental health advocacy...

15d ago

AXSM

Axsome Therapeutics initiated with a Buy at B. Riley

B. Riley analyst Madison El-Saadi initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $179 price...

23d ago

AXSM

Axsome Therapeutics initiated with a Buy at B. Riley

B. Riley analyst Madison El-Saadi initiated coverage of Axsome Therapeutics (AXSM) with a Buy rating and $179 price...

24d ago

AXSM

Axsome Therapeutics: Strategic Growth and Promising Commercial Progress Drive Buy Rating

Morgan Stanley analyst Sean Laaman has maintained their bullish stance on AXSM stock, giving a Buy rating on...

4d ago

AXSM

Axsome Therapeutics: Strong Growth Trajectory and Financial Outlook Justify Buy Rating

William Blair analyst Myles Minter has maintained their bullish stance on AXSM stock, giving a Buy rating on...

1M ago

AXSM

RBC lists biotech winners should RFK depart HHS

RBC Capital explores the implications on biotech stocks of Robert F. Kennedy Jr. potentially departing the Health and...

1M ago

ALKS

AXSM

RBC lists biotech winners should RFK departure HHS

RBC Capital explores the implications on biotech stocks of Robert F. Kennedy Jr. potentially departing the Health and...

1M ago

ALKS

AXSM

Axsome Therapeutics assumed with an Overweight at Wells Fargo

Wells Fargo assumed coverage of Axsome Therapeutics (AXSM) with an Overweight rating and $163 price target The firm...

2M ago

AXSM

Positive Outlook for Axsome Therapeutics Amidst SYMBRAVO’s Market Expansion and Patent Strength

H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Axsome Therapeutics today and set a price target...

2M ago

AXSM

Axsome Therapeutics Receives Paragraph IV Certification Notice

The latest update is out from Axsome Therapeutics ( ($AXSM) ). On August 19, 2025, Axsome Therapeutics received...

2M ago

AXSM

Axsome Therapeutics management to meet with Needham

Meeting to be held in New York on August 12 hosted by Needham. Published first on TheFly –...

2M ago

AXSM

Axsome Therapeutics: Strong Sales Performance and Promising Growth Trajectory Reinforce Buy Recommendation

Analyst Marc Goodman of Leerink Partners maintained a Buy rating on Axsome Therapeutics, with a price target of...

3M ago

AXSM

Axsome Therapeutics: Strong Growth Prospects and Strategic Investments Justify Buy Rating

Analyst Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Axsome Therapeutics and keeping the price target...

3M ago

AXSM

AXSM FAQ

What was Axsome Therapeutics Inc’s price range in the past 12 months?

Axsome Therapeutics Inc lowest stock price was $75.56 and its highest was $139.13 in the past 12 months.

What is Axsome Therapeutics Inc’s market cap?

Axsome Therapeutics Inc’s market cap is $6.47B.

When is Axsome Therapeutics Inc’s upcoming earnings report date?

Axsome Therapeutics Inc’s upcoming earnings report date is Nov 03, 2025 which is in 10 days.

How were Axsome Therapeutics Inc’s earnings last quarter?

Axsome Therapeutics Inc released its earnings results on Aug 04, 2025. The company reported -$0.97 earnings per share for the quarter, beating the consensus estimate of -$1.055 by $0.085.

Is Axsome Therapeutics Inc overvalued?

According to Wall Street analysts Axsome Therapeutics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Axsome Therapeutics Inc pay dividends?

Axsome Therapeutics Inc does not currently pay dividends.

What is Axsome Therapeutics Inc’s EPS estimate?

Axsome Therapeutics Inc’s EPS estimate is -0.87.

How many shares outstanding does Axsome Therapeutics Inc have?

Axsome Therapeutics Inc has 49,901,485 shares outstanding.

What happened to Axsome Therapeutics Inc’s price movement after its last earnings report?

Axsome Therapeutics Inc reported an EPS of -$0.97 in its last earnings report, beating expectations of -$1.055. Following the earnings report the stock price went up 3.417%.

Which hedge fund is a major shareholder of Axsome Therapeutics Inc?

Currently, no hedge funds are holding shares in AXSM

Axsome Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

-280.68%

Trailing 12-Months

Asset Growth

16.70%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Axsome Therapeutics Inc

Axsome Therapeutics (AXSM) is a clinical-stage biopharmaceutical company focused on developing novel therapies for the management of central nervous system (CNS) disorders. The company's primary areas of interest include depression, pain, and addiction, with a robust pipeline of candidates aimed at addressing significant unmet medical needs. Axsome's lead product, AXS-05, is a multimodal investigational drug for the treatment of major depressive disorder and other indications, while AXS-07 is designed for the acute treatment of migraine. Through its innovative approach to drug development, Axsome aims to improve the quality of life for patients with complex CNS conditions.

Axsome Therapeutics (AXSM) Earnings & Revenues

Historic Earnings Reports

AXSM Company Deck

AXSM Earnings Call

Q2 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call presented a generally positive outlook with significant revenue growth and successful product launches. However, the substantial net loss and challenges in market access for SYMBRAVO present areas for concern.View all AXSM earnings summaries

AXSM Stock 12 Month Forecast

Average Price Target

$173.25

▲(36.35% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"83":"$83","142":"$142","201":"$201","112.5":"$112.5","171.5":"$171.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":173.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$173.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":148,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$148.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[83,112.5,142,171.5,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2025","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.57,124.83384615384615,131.0976923076923,137.36153846153846,143.6253846153846,149.88923076923078,156.15307692307692,162.41692307692307,168.68076923076922,174.9446153846154,181.20846153846153,187.4723076923077,193.73615384615385,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.57,122.77615384615385,126.98230769230769,131.18846153846152,135.39461538461538,139.60076923076923,143.80692307692308,148.01307692307694,152.21923076923076,156.42538461538462,160.63153846153847,164.8376923076923,169.04384615384618,{"y":173.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,118.57,120.83384615384615,123.0976923076923,125.36153846153846,127.6253846153846,129.88923076923078,132.15307692307692,134.41692307692307,136.68076923076922,138.9446153846154,141.20846153846153,143.4723076923077,145.73615384615385,{"y":148,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":90.51,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.84,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 49,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":99.08,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.61,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 65,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":106.46,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 75,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":127.54,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 81,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":111.67,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 77,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.24,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":107.66,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":102.97,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":103.02,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":123.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 42,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":118.57,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >